Cerebrolysin is a peptide preparation made from pig brain protein. It is authorised as a prescription medicine in some countries outside the United States, mainly for stroke, dementia and brain injury. The FDA has not approved it. This guide covers its makeup, proposed mechanism, key trials, side effects and status. Sources were checked on November 17, 2026.
Quick answer: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain. EVER Neuro Pharma in Austria makes it. National regulators in Austria and Croatia list it as an authorised medicine. The manufacturer states it is not registered with the FDA. Stroke trial results are mixed.
Vitrapep does not sell cerebrolysin; this page is a reference summary of published research and regulatory information.
What is cerebrolysin?
Cerebrolysin is not a single molecule. A Cochrane review describes it as “a mixture of low-molecular-weight peptides and amino acids derived from porcine brain” (Ziganshina et al., 2023). The Austrian package leaflet calls it a peptide preparation obtained from pig brain protein (Austrian leaflet, 2021).
Because it is a mixture, it has no single molecular formula or weight. It counts as a peptide product because its active content is a peptide mixture rather than one defined sequence. Our guides to what peptides are and peptides versus proteins explain the difference between short fragments and whole proteins.
The marketing authorisation holder is EVER Neuro Pharma GmbH, based in Unterach am Attersee, Austria. Croatia’s medicines agency lists the product as authorised, marketed and prescription-only, under ATC code N07X (HALMED).
Cerebrolysin: key facts
| Fact | Detail |
|---|---|
| Structure type | Mixture of low-molecular-weight peptides and amino acids from porcine brain |
| Class | Neuropeptide preparation (ATC code N07X) |
| Molecular formula | Not applicable (a mixture, not one molecule) |
| Molecular weight | Not applicable (described as low-molecular-weight components) |
| Development stage | Marketed outside the US; phase 2 trial in CADASIL listed as active (2026) |
| Sponsor or developer | EVER Neuro Pharma GmbH, Austria |
| Approved outside the US | National authorisations, including Austria and Croatia; first approval year not verified |
How does cerebrolysin work?
Its proposed mechanism comes mainly from animal studies. One research group describes it as “a mixture of neurotrophic peptides,” meaning peptides that support nerve-cell growth and survival (Zhang et al., 2013). The Austrian leaflet states its purpose as supporting brain function.
In rats with embolic stroke, cerebrolysin enhanced the formation of new neurons and oligodendrocytes. It also increased axon remodeling near the injury and improved neurological recovery. Blocking the Sonic hedgehog signaling pathway with cyclopamine reversed these effects. The authors concluded that this pathway mediates the benefits seen in rats. These are animal data, and a single defined mechanism in people has not been shown in the sources we checked.
What is cerebrolysin being studied for?
Cerebrolysin is not approved by the FDA for any use. Its maker states that it is not registered with the FDA or approved for sale in the United States (EVER Neuro Pharma).
In Austria, the leaflet lists supportive treatment of cerebrovascular disorders in adults, in particular:
- Alzheimer-type dementia and vascular dementia;
- deficits remaining after a stroke; and
- traumatic brain injury (concussion and contusion).
The Cochrane review says cerebrolysin is widely used for acute ischemic stroke in Russia, Eastern Europe and China. It also notes listings on national essential medicines lists, including Slovakia, Romania, Vietnam and Uganda (Ziganshina et al., 2023).
ClinicalTrials.gov lists 43 studies with cerebrolysin as an intervention (ClinicalTrials.gov). Recent ones cover stroke recovery, aphasia, brain hemorrhage, traumatic brain injury and delirium. Most recent studies are run by hospitals and universities. EVER Neuro Pharma sponsors a phase 2 trial in CADASIL, listed as active and not recruiting (NCT05755997). Its stroke registry study, which enrolled 1,851 patients, was completed in 2024 (NCT03480698).
What did the key trials show?
CASTA, acute ischemic stroke. This double-blind, placebo-controlled trial in Asia randomized 1,070 patients within 12 hours of stroke onset. There were 529 in the cerebrolysin group and 541 in the placebo group. The primary outcome combined the modified Rankin Scale, Barthel Index and NIH Stroke Scale. The authors wrote that “the confirmatory end point showed no significant difference between the treatment groups” (Heiss et al., 2012). EVER Neuro Pharma is the registry sponsor (NCT00868283).
CARS, stroke rehabilitation. This randomized, double-blind, placebo-controlled, multicenter trial added cerebrolysin or placebo to standardized rehabilitation. The primary outcome was the Action Research Arm Test of arm function on day 90. The authors reported an effect size of 0.71 (95% CI 0.63 to 0.79; P < 0.0001) in favor of cerebrolysin (Muresanu et al., 2016). They noted a relatively small sample size. One author lists an EVER Neuro Pharma affiliation.
Cochrane review, acute ischemic stroke. The 2023 update pooled 7 randomized trials with 1,773 participants. One included trial tested Cortexin, a similar brain-derived product. For all-cause death, the risk ratio was 0.96 (95% CI 0.65 to 1.41; 6 trials, 1,689 participants). The authors rated this as moderate-certainty evidence of little or no difference (Ziganshina et al., 2023). All three sources describe human data.
What side effects have studies reported?
The Cochrane review found “little to no difference” in the total number of people with serious adverse events. The risk ratio was 1.16 (95% CI 0.81 to 1.66; 3 trials, 1,335 participants). It did find more non-fatal serious adverse events: risk ratio 2.39 (95% CI 1.10 to 5.23; 3 trials) (Ziganshina et al., 2023). The CARS authors reported safety comparable to placebo.
The Austrian package leaflet lists these effects:
- Rare: agitation (aggression, confusion, insomnia), loss of appetite, dizziness, a feeling of heat or sweating, and itching.
- Very rare: allergic reactions, isolated seizures, palpitations or heart-rhythm disturbances, indigestion, nausea, vomiting, diarrhoea and constipation (Austrian leaflet, 2021).
What is cerebrolysin’s regulatory status, and how is it used in research?
In the United States, cerebrolysin has no FDA approval and, per its maker, no FDA registration. A search of fda.gov returned no FDA document naming it. The approvals we could confirm are national ones. Austria’s agency hosts its leaflet, and Croatia’s HALMED lists it as authorised and marketed. The Cochrane review adds that the manufacturer supported three of the multicentre trials it included.
In laboratories, cerebrolysin is used in animal models of stroke and brain injury, such as the rat stroke work above. For how unapproved compounds are labeled and sold for laboratory work, see research use only, explained. For other brain-targeted peptides, see semax and davunetide.
Frequently asked questions about cerebrolysin
Is cerebrolysin a peptide?
It is a peptide mixture, not one peptide. It contains low-molecular-weight peptides and amino acids derived from pig brain.
Is cerebrolysin FDA approved?
No. Its manufacturer states it is not registered with the FDA and not approved for sale in the United States.
Where is cerebrolysin approved?
We confirmed national authorisations in Austria and Croatia. A Cochrane review reports wide use in Russia, Eastern Europe and China.
Does cerebrolysin improve stroke outcomes?
Evidence is mixed. The largest trial missed its primary endpoint, while the smaller CARS trial reported better arm function. A Cochrane review found little or no difference in death.
Who makes cerebrolysin?
EVER Neuro Pharma GmbH in Austria holds the marketing authorisations we found.
What to know now
- Makeup: mixture of low-molecular-weight peptides and amino acids from porcine brain.
- Status: not FDA-approved; authorised nationally in Austria and Croatia, among others.
- Evidence: CASTA (1,070 patients) missed its primary endpoint; CARS reported better arm function.
- Review: Cochrane found little or no difference in death after acute ischemic stroke.
- Safety: non-fatal serious adverse events higher in pooled trials (RR 2.39).
- Maker: EVER Neuro Pharma GmbH, Austria.
What we’re watching
Results from EVER Neuro Pharma’s phase 2 trial in CADASIL, with completion estimated for December 2026. Publication of its completed stroke registry study. Any future Cochrane update. Related guides: davunetide, NNZ-2591 and semax.